U.S. Markets closed

Can 'synthetic lethality' and deep experience propel this cancer-fighting biotech's $70M IPO?

Ron Leuty
Can 'synthetic lethality' and deep experience propel this cancer-fighting biotech's $70M IPO?

This Peninsula drug developer has four preclinical drugs aimed at triggering a process that it believes will kill cancer cells with genetic mutations.